UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Venetoclax Resistance in Acute Myeloid Leukemia

Cancers, 2024-03, Vol.16 (6), p.1091

2024

Volltextzugriff (PDF)

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance

Cancers, 2021-11, Vol.13 (22), p.5608

2021

Volltextzugriff (PDF)

Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity

Nucleic acids research, 2018-04, Vol.46 (7), p.3339

2018

Volltextzugriff (PDF)

Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF

PloS one, 2020-03, Vol.15 (3), p.e0228878-e0228878

2020

Volltextzugriff (PDF)

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study

Bone marrow transplantation (Basingstoke), 2022-04, Vol.57 (4), p.627-632

2022

Volltextzugriff (PDF)

Downregulation of stromal syntenin sustains AML development

EMBO molecular medicine, 2023-11, Vol.15 (11), p.e17570-e17570

2023

Volltextzugriff (PDF)

Caspase-2 protects against ferroptotic cell death

Cell death & disease, 2024-03, Vol.15 (3), p.182-182, Article 182

2024

Volltextzugriff (PDF)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

Cancers, 2022-04, Vol.14 (8), p.2025

2022

Volltextzugriff (PDF)

Patients' Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings

PloS one, 2016-05, Vol.11 (5), p.e0154969-e0154969

2016

Volltextzugriff (PDF)

Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites

Haematologica (Roma), 2015-04, Vol.100 (4), p.e155

2015

Volltextzugriff (PDF)

P548: PRELIMINARY RESULTS OF A PHASE 1, FIRST‐IN‐HUMAN STUDY OF INA03, AN ANTI‐CD71 ANTIBODY‐DRUG CONJUGATE IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LEUKEMIAS

HemaSphere, 2023-08, Vol.7 (S3), p.e45170e9-n/a

2023

Volltextzugriff (PDF)

Erythroleukemia: Classification

EJHaem, 2023-05, Vol.4 (2), p.450-453

2023

Volltextzugriff (PDF)

PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO‐BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER

HemaSphere, 2023-08, Vol.7 (S3), p.e4520163-n/a

2023

Volltextzugriff (PDF)

P494: A FIRST‐IN‐HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK‐MYELODYSPLASIA

HemaSphere, 2023-08, Vol.7 (S3), p.e66387cd-n/a

2023

Volltextzugriff (PDF)

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

Haematologica (Roma), 2015-10, Vol.100 (10), p.e423

2015

Volltextzugriff (PDF)

Cancer : le besoin de croire

Bulletin du cancer, 2024-06, Vol.111 (6), p.550-551

2024

Volltextzugriff (PDF)

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile

OncoTargets and therapy, 2023-01, Vol.16, p.31-45

2023

Volltextzugriff (PDF)

Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7045-7045

2023

Volltextzugriff (PDF)

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.7800-7801

2022

Volltextzugriff (PDF)

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Blood, 2022-11, Vol.140 (Supplement 1), p.6147-6148

2022

Volltextzugriff (PDF)

Rituximab‐ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy

British journal of haematology, 2016-11, Vol.175 (4), p.735-737

2016

Volltextzugriff (PDF)

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Blood, 2020-11, Vol.136 (Supplement 1), p.39-40

2020

Volltextzugriff (PDF)

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Blood, 2020-11, Vol.136 (Supplement 1), p.23-23

2020

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(34)
Humans
(23)
Oncology
(21)
Hematology
(18)
Life Sciences
(13)
Cancer
(11)
Male
(11)
Acute Myeloid Leukemia
(10)
Adult
(10)
Female
(10)
Middle Aged
(10)
Chemotherapy
(9)
Leukemia
(9)
Mutation
(9)
Aged
(8)
Patients
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Lymphoma
(7)
Stem Cell Transplantation
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Venetoclax Resistance in Acute Myeloid Leukemia

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity

Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study

Downregulation of stromal syntenin sustains AML development

Caspase-2 protects against ferroptotic cell death

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

Patients' Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings

Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites

P548: PRELIMINARY RESULTS OF A PHASE 1, FIRST‐IN‐HUMAN STUDY OF INA03, AN ANTI‐CD71 ANTIBODY‐DRUG CONJUGATE IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LEUKEMIAS

Erythroleukemia: Classification

PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO‐BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER

P494: A FIRST‐IN‐HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK‐MYELODYSPLASIA

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

Cancer : le besoin de croire

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile

Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Rituximab‐ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Long Term Analysis of a Monocentric Cohort of Therapy-Related Acute Lymphoblastic Leukemia

Suchergebnisse filtern